Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder

Patient Preference and Adherence

Volumn 6, Issue , 2012, Pages 623-629

  Medina, Esteban ^a   Salvà, Joan ^b   Ampudia, Rubén ^c   Maurino, Jorge ^a   Larumbe, Juan ^d  

^a AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c IQVIA   (United States)

^d Hospital Psiquiatrico de Alava   (Spain)

Author keywords

Attitude towards treatment; Bipolar disorder; Discharge; Insight; Schizophrenia; Therapeutic adherence

Indexed keywords

NEUROLEPTIC AGENT;

10 ITEM DRUG ATTITUDE INVENTORY; ADULT; AGE; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE DURATION; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; RATING OF MEDICATION INFLUENCES SCALE; SCALE OF UNAWARENESS OF MENTAL DISORDERS; SCHIZOPHRENIA; SCORING SYSTEM; SELF REPORT;

EID: 84872827623     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S34345     Document Type: Article

References (43)

1. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46.
2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
3. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67:453-460.
4. Gianfrancesco FD, Sajatovic M, Rajagopalan K, Wang RH. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30:1358-1374.
5. Fleischhacker WW, Oehl MA, Hummer M. Factors influencing compliance in schizophrenia patients. J Clin Psychiatry. 2003;64(Suppl 16): 10-13.
6. Rossi A, Pacifico R, Stratta P. Attitudes toward medication and the clinical variables in schizophrenia: Structural equation models. Patient Prefer Adherence. 2009;3:305-309.
7. Schennach-Wolff R, Jäger M, Seemüller F, et al. Attitude towards adherence in patients with schizophrenia at discharge. J Psychiatr Res. 2009;43:1294-1301.
8. Maurino J, Cordero L, Ballesteros J. The subjective well-being under neuroleptic scale-short version (SWN-K) and the SF-36 health survey as quality of life measures in patients with schizophrenia. Patient Prefer Adherence. 2012;6:83-85.
9. Gonzalez-Pinto A, Reed C, Novick D, Bertsch J, Haro JM. Assessment of medication in a cohort of patients with bipolar disorder. Pharmacopsychiatry. 2010;43:263-270.
10. Julius RJ, Novitsky MA, Dubin WR. Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract. 2009;15:34-44.
11. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108.
12. Gharabawi GM, Greenspan A, Rupnow MF, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry. 2006;6:45.
13. Beck EM, Vögelin R, Wirtz M, Cavelti M, Kvrgic S, Vauth R. Do patients with schizophrenia distinguish between attitudes toward antipsychotic medication and pharmacotherapy in general? Validation of the Beliefs about Medication Questionnaire. J Nerv Ment Dis. 2012;200: 33-43.
14. Nordon C, Rouillon F, Barry C, Gasquet I, Falissard B. Determinants of treatment satisfaction of schizophrenia patients: results from the ESPASS study. Schizophr Res. 2012;139:211-217.
15. Donohoe G, Owens N, O'Donnell C, et al. Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis. Eur Psychiatry. 2001;16:293-298.
16. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13:177-183.
17. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull. 1993;19:609-618.
18. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297-310.
19. Freudenreich O, Cather C, Evins AE, Henderson DC, Goff DC. Attitudes of schizophrenia outpatients toward psychiatric medications: relationship to clinical variables and insight. J Clin Psychiatry. 2004;65: 1372-1376.
20. Barberá M, Sanjuán J, Munárriz M, Novella E, Santiago C, Simó M. Subjective experience with antipsychotics: quantitative evaluation. Actas Esp Psiquiatr. 2006;34:287-294. Spanish.
21. Amador XF, Strauss DH, Yale SA, Flaum MM, Endicott J, Gorman JM. Assessment of insight in psychosis. Am J Psychiatry. 1993;150: 873-879.
22. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand. 1987;76 (Suppl s334):1-100.
23. García-Cabeza I, Gomez JC, Sacristan JA, Edgell E, Gonzalez de Chavez M. Subjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study). BMC Psychiatry. 2001;1:7.
24. Beck E-M, Cavelti M, Kvrgic S, Kleim B, Vauth R. Are we addressing the "right stuff" to enhance adherence in schizophrenia? Understanding the role of insight and attitudes towards medication. Schizophr Res. 2011;132:42-49.
25. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2011;71(Suppl 2):20-26.
26. Adams J, Scott J. Predicting medication adherence in severe mental disorders. Acta Psychiatr Scand. 2001;101:119-124.
27. Day JC, Bentall RP, Roberts C, et al. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch Gen Psychiatry. 2005;62:717-724.
28. Yen CF, Chen CS, Ko CH, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci. 2005;59:403-409.
29. Scott J, Pope M. Nonadherence with mood stabilizers: prevalence and predictors. J Clin Psychiatry. 2002;63:384-390.
30. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M. A self-report Insight Scale for psychosis: reliability, validity, and sensitivity to change. Acta Psychiatr Scand. 1994;89:62-67.
31. Nielsen RE, Lindström E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012; doi:10.1016/j.euroneuro.2012.02.008.
32. Liu-Seifert H, Osuntokun OO, Godfrey JL, Feldman PD. Patient perspectives on antipsychotic treatments and their association with clinical outcomes. Patient Prefer Adherence. 2010;4:369-377.
33. Yang J, Ko YH, Lee MS, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134:226-231.
34. Hofer A, Rettenbacher MA, Edlinger M, Kemmler G, Widschwendter CG, Fleischhacker WW. Subjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand. 2007;116:354-361.
35. Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44:921-928.
36. Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. Schizophr Bull. 2009;35:336-346.
37. Lambert M, Conus P, Eide P, et al. Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry. 2004;19:415-422.
38. Taira M, Hashimoto T, Takamatsu T, Maeda K. Subjective response to neuroleptics: the effect of a questionnaire about neuroleptic side effects. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:1139-1142.
39. Agyapong VI, Nwankwo V, Bangaru R, Kirrane R. Sources of patients' knowledge of the adverse effects of psychotropic medication and the perceived influence of adverse effects on compliance among service users attending community mental health services. J Clin Psychopharmacol. 2009;29:565-570.
40. Lysaker PH, Buck KD, Salvatore G, Popolo R, Dimaggio G. Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches. Expert Rev Neurother. 2009;9:1035-1043.
41. Crowe M, Porter R, Inder M, Lacey C, Carlyle D, Wilson L. Effectiveness of interventions to improve medication adherence in bipolar disorder. Aust N Z J Psychiatry. 2012;46:317-326.
42. Montes JM, Maurino J, Diez T, Saiz-Ruiz J. Factors associated with the effectiveness of a telephone-based nursing strategy for enhancing medication adherence in schizophrenia. Clin Pract Epidemiol Ment Health. 2011;7:117-119.
43. Barkhof E, Meijer CJ, de Sonneville LMJ, Linszen DH, de Hann L. Interventions to improve adherence to antipsychotic medication in patients with schizophrenia-A review of the past decade. Eur Psychiatry. 2012;27:9-18.